Allergan Acquisition Spree? Some Potential Big Targets

The aftermath of the Allergan divestiture and acquisition event is currently being digested by Wall Street, because the repercussions are likely to be larger than just the single day news. The move by Allergan is a transformative shift and an RBC Capital Markets research note looks at what could become a major trend. What could surprise institutional investors, the analysis notes, is the size of the acquisition spree.

RBC: “Investors legitimately believe that the Allergan deal… is a sign that it is theoretically possible that large-cap biotech companies” are now in play

What was interesting about the July 28 note was that the scope of the dots that are now being publically connected.  Allergan could not only acquire smaller niche...